De novo manifestations during adalimumab treatment in Behçet's syndrome.
Sinem Nihal EsatogluOzge SonmezDidar UcarElif KaymazYesim OzgulerSerdal UgurluEmire SeyahiMelike MelikogluIzzet FreskoVedat HamuryudanUgur UygunogluZekayi KutlubayAli Ibrahim HatemiAykut Ferhat CelikGulen HatemiPublished in: Rheumatology (Oxford, England) (2024)
De novo manifestations were infrequent (4%) among BS patients treated with adalimumab. Of these, 57% were major organ involvement, mainly vascular involvement. None of the patients developed posterior uveitis.